<DOC>
	<DOC>NCT00247247</DOC>
	<brief_summary>Multi-centre, randomised, parallel-group study, rater-blinded. Total duration of the study per subject is 12 weeks plus a one- to two-week screening period. There are 6 pre-planned visits per subject: screening visit followed by 5 visits. Approximately 300 patients altogether in up to 25 active German study centres and up to 3 active Lithuanian study centres will be randomised.</brief_summary>
	<brief_title>Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing- Off.</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Cabergoline</mesh_term>
	<mesh_term>Entacapone</mesh_term>
	<criteria>patients suffering from idiopathic Parkinson's Disease (PD) with wearingoff phenomenon OFFtime per day &gt;= 60 min after the first ONperiod in the morning 35 daily dosages of standard levodopa/DDC inhibitor stable antiparkinsonian treatment 3 weeks prior to the randomisation symptomatic parkinsonism concomitant treatment with nonselective MAO inhibitors or a selective MAOA inhibitor while treated with a MAOB inhibitor already concomitant treatment with one of the following catecholstructured drugs: rimiterol, isoprenaline, adrenaline, noradrenaline, dopamine, dobutamine or apomorphine concomitant treatment with alphamethyldopa, reserpine, typical or atypical neuroleptics, neuroleptic antiemetics (such as metoclopramide) or other drugs with antidopaminergic action treatment with COMTinhibitors 4 weeks prior to the randomisation treatment with dopamine agonists 4 weeks prior to the randomisation known hypersensitivity to ergot derivatives and entacapone dementia (MMSE &lt;= 24) depression (Beck Scale &gt;= 17)</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>